ONCAlert | Upfront Therapy for mRCC
Videos  >  

Comparing Results for 80 mg versus 160 mg Osimertinib in Advanced EGFR+ NSCLC

Myung-Ju Ahn, MD
Published Online:4:41 PM, Thu May 16, 2019


Myung-Ju Ahn, MD, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, discusses the findings from the AURA LM study, which compared an 80 mg dose of osimertinib (Tagrisso) with a 160 mg dose in patients with EGFR-positive advanced non–small cell lung cancer with leptomeningeal metastases (LM).

Data was compared in an analysis from 4 studies in the AURA program, says Ahn. The LM response rate was 55%, and the LM progression-free survival was 11.1 months. The median overall survival was 18.8 months.

The study aimed to evaluate whether this lower dose had similar efficacy to the doubled dose of osimertinib in this patient population. An explorative analysis comparing results in the BLOOM study demonstrated the 80 mg dose might have similar efficacy.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.